Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder causing progressive heterotopic ossification.
• Over 95% of FOP cases stem from a specific mutation (R206H) in the ACVR1/ALK2 receptor.
• Aberrant activation of ACVR1^R206H by activin A drives heterotopic ossification in FOP.

Purpose of the Study:

• To develop a therapeutic strategy targeting ACVR1 expression in FOP.
• To investigate the use of exon skipping to reduce ACVR1 mRNA levels.
• To explore the potential of phosphorodiamidate morpholino oligomers (PMOs) for gene knockdown.

Main Methods:

• Utilized exon skipping in ACVR1 messenger RNAs (mRNAs).
• Employed phosphorodiamidate morpholino oligomers (PMOs) to induce exon skipping.
• Applied the method to FOP patient-derived cells.

Main Results:

• Successfully reduced ACVR1 expression in FOP patient cells.
• Demonstrated the feasibility of using PMOs for targeted gene knockdown.
• Established a screening method for identifying effective antisense oligomers.

Conclusions:

• Exon skipping with PMOs is a viable strategy to decrease ACVR1 expression in FOP.
• This approach holds promise for treating FOP and other autosomal-dominant genetic diseases.
• The developed method can be adapted for screening therapeutic antisense oligomers.